News | August 21, 2012

New Study Shows Positive Results for IOERT APBI Treatment

August 21, 2012 — Ospedale Borgo Trento in Verona, Italy, recently published a study of 226 women with early-stage breast cancer that received a single dose of intraoperative electron radiation therapy (IOERT) using the IntraOp Mobetron from IntraOp Medical Corp. during surgery. 

There was only one local recurrence after a mean follow-up of almost four years. The study was published by the University of Verona in the International Journal of Radiation Oncology, Biology and Physics, the professional journal for the American Society of Therapeutic Radiation Oncologists (ASTRO). This one-day treatment is called accelerated partial breast irradiation (APBI) with IOERT, or IOERT APBI.

There are several other APBI techniques that are currently under study, designed to shorten the 5-7 weeks of radiation that women with early-stage breast cancer normally require. These other APBI techniques range from one-day treatments like IOERT to five-day treatments, with some occurring during surgery and some as many as 2-3 weeks after surgery. IOERT APBI is the only breast treatment technique that is done on the day of surgery and in one 2-minute treatment, with no further radiation required.

"Single-dose IOERT in early-stage breast cancer can be delivered safely and with excellent results," said Sergio Maluta, professor emeritus at the University of Verona and principal investigator for the Verona study.  "Patients at low risk of local recurrence represent an excellent group to receive a one-dose procedure and avoid six weeks postoperative radiation treatment."

ASTRO has identified low-risk women that are suitable for APBI treatments outside of a clinical trial.  These are women over 60 years old with small tumors and favorable biology with no involved lymph nodes. "These low-risk women are about 30 percent of the U.S. breast cancer population," said Don Goer, Ph.D., IntraOp Medical's chief scientist. "That means about 75,000 women per year in the U.S. could be eligible for a one-day treatment using ASTRO criteria for APBI."

"The University of Verona results are also consistent with the data coming from the European Institute of Oncology (EIO)," added Goer. "Their randomized trial comparing IOERT APBI with the standard six weeks of radiation therapy has now been presented at a number of international meetings and is being prepared for publication this fall. In their presentations the EIO showed that the long-term (5-year median follow-up) recurrence rates were 1.5 percent for ASTRO-suitable women treated with IOERT ABPI, equivalent to the ASTRO-suitable women treated with the standard six-week procedure. These low recurrence rates of 1.5 percent at five years were also seen for ASTRO-suitable women in another EIO-published study of 1,822 women treated with IOERT APBI outside of the trial."

For more information: www.intraopmedical.com

Related Content

New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
Warm Springs Health & Wellness Center Implements Digisonics Solution for OB Ultrasound
News | Ultrasound Women's Health | June 17, 2019
Warm Springs Health & Wellness Center in Warm Springs, Ore., has selected the Digisonics OB PACS (picture archiving...
Fujifilm Announces Nationwide Breast Health Campaign With Mobile Mammography Coach

At the center of the campaign, Fujifilm will be traveling around the U.S. with its "Aspire to Be Fearless" mobile mammography coach to provide educational opportunities for clinicians, raise awareness about the importance of screening and will be providing mammograms to the underserved population in key locations.

News | Mammography | June 14, 2019
Fujifilm Medical Systems U.S.A. Inc. announced a nationwide awareness campaign titled ‘Aspire to Be Fearless’ focused...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
Ikonopedia Showcases Risk Assessment and Resolution Manager Tools at SIIM and AHRA
News | Mammography Reporting Software | June 13, 2019
Ikonopedia will showcase its suite of structured breast reporting and Mammography Quality Standards Act (MQSA)...
Sponsored Content | Videos | Radiology Imaging | June 13, 2019
In an interview with itnTV, Henry Izawa, vice president, modality solutions and clinical affairs, Fujifilm Medical Sy
iCAD Introduces ProFound AI for 2D Mammography in Europe
News | Artificial Intelligence | June 13, 2019
iCAD Inc. announced the launch of ProFound AI for 2D Mammography in Europe. This software is the latest addition to...
Three Palm Software Releases WorkstationOne Version 1.8.8
Technology | Mammography Reporting Software | June 12, 2019
Three Palm Software announced the release of the 1.8.8 version of its breast imaging workstation, WorkstationOne. This...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...